Japanese Ministry Of Health Approves Rasilez(R), A First-in-class Direct Renin Inhibitor (DRI), For The Treatment Of High Blood Pressure
Rasilez® (aliskiren), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. Rasilez directly inhibits renin9, an enzyme that triggers a process leading to high blood pressure and organ damage. The Ministry of Health, Labour and Welfare (MHLW) in Japan approved Rasilez for the treatment of high blood pressure alone or in combination with other high blood pressure medicines.
Health Insurance
Pages: 1 [2]
European College Of Neuropsychopharmacology, 22nd Congress Sept. 12-16, 2009, Turkey
a unique and remarkably broad interdisciplinary platform, which strongly emphasises the complementary nature of research at the bench and at the bedside or clinic. This so-called ÷“translational research÷“ is target-oriented, promoting the development of diagnostic procedures and laboratory outcomes in the service of discoveries that will result in improved patient care (Zerhouni 2005). To facilitate the flow of information among researchers and clinicians, ECNP has set up in recent years a number of activities stimulating cross-disciplinary forces - ranging from psychiatry to neurology, pharmacology and psychology - to carry out research on brain mechanisms and functions. Recently the ECNP School of Neuropsychopharmacology has been established with the aim to teach junior clinicians high standard practice in neuropsychopharmacology and to involve them in the development of local good practice in teaching and training. The first ECNP School of Neuropsychopharmacology was held in Oxford, UK, from 5 July 2009. ECNP is dedicated to the progressive integration of basic research, clinical neuroscience and medical practice, which can guide advances in neuropsychopharmacology and lead to a next generation of promising new treatments for mental disorders. Highlights of the 22nd ECNP Congress 2009 From 12 September 2009, renowned experts from 25 countries will meet in Istanbul to present, discuss and evaluate the latest achievements and future perspectives in the fields of affective disorders, schizophrenia, drugs & addiction, brain plasticity, basic neuroscience and psychopharmacology. Great emphasis will be put on clear take-home messages that can easily be translated into clinical practice by medical professionals. The scientific programme includes over 100 topics to be presented by more than 600 experts, and will comprise, among others, the following topics: * The role of genetic factors in adult ADHD * The future of schizophrenia * Are the monoamines involved in shaping conduct disorder? * Vaccination for Alzheimer÷“s disease in dementia * Novel treatment for smoking * Maternal serotonin * Deep Brain Stimulation (DBS): new perspectives for treatment * News on the NewMood project The educational update sessions at the ECNP Congress will deal with the current knowledge on GABA and biomarkers in neuropsychopharmacology, treatment of insomnia, bipolar disorders and schizophrenia, as well as the new classification systems ICD-11 and DSM-V. Three poster sessions with in total more than 900 poster presentations from scientists from all over the world will offer an exciting insight into the research activities of (young) scientists. Furthermore, ECNP is proud to present the report of the ECNP Consultation Meeting 2009 on "Biomarkers and experimental medicine in developing new treatments in neuropsychopharmacology". Through annual consultation meetings on specific topics, ECNP aims to facilitate the dialogue and exchange advice between the participating parties, i.e. scientists, regulatory authorities and the pharmaceutical industry. The high-calibre and well-balanced programme of the 22nd ECNP Congress is dedicated to promoting the dissemination of new research findings and the exchange of ideas and information among clinicians and scientists in order to improve the situation of people struck by mental disorders. References * Garner M, Mē¶hler H, Stein DJ, et al. Research in anxiety disorders: from the bench to the bedside. Eur Neuropsychopharmacol 2009;19(6):381-390 * Janē©-Llopis E; Anderson P (Eds.) Mental health promotion and mental disorder prevention across European Member States. Luxembourg: European Communities, 2006 * Janē©-Llopis E; Barry M, Patel V, Hosman C (Eds.). The evidence of mental health promotion: strategies for action. Promotion and Education, Supplement 2, 2005. * Janē©-Llopis E; Gabilondo A (Eds.). Mental Health in Older People. Consensus Paper. Luxembourg: European Communities, 2008 * Kuhn HG, Cooper-Kuhn CM, Boekhoorn K, Lucassen PJ. Changes in neurogenesis in dementia and Alzheimer mouse models: are they functionally relevant? Eur Arch Psychiatry Clin Neurosci 2007;257(5):281-289 * McDaid (Ed.). Mental Health in Workplace Settings. Consensus Paper. Luxembourg: European Communities, 2008 * Ogren SO, Eriksson TM, Elvander-Tottie E, et al. The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res 2008;195(1):54-77 * Pachter P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462 * Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nature Neuroscience 2007;10:1110-1115 * World Health Organization (WHO). Policies and practices for mental health in Europe - meeting the challenges. WHO Regional Office for Europe, Copenhagen, 2008 * Zerhouni EA. Translational and clinical science - time for a new vision. N Engl J Med 2005;33:1621-1623 Sonja Mak European College of NeuropsychopharmacologyPages: 1 [2]